A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX)

Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX)

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms REFLEX
  • Sponsors Merck KGaA
  • Most Recent Events

    • 27 Jun 2017 Results (n=917) assessing predictive value of modified Rio score using patient data from REFLEX(ION), REGARD, SPECTRIMS and PRISMS trials presented at the 3rd Congress of the European Academy of Neurology
    • 28 Apr 2017 Results of post-hoc analysis conducted in the intent-to-treat population of this and REFLEXION trial presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results (n=407) of exploratory analysis assessing effect of interferon beta -1a SC on lesion appearance in specific, clinically relevant brain regions, presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top